Abstract 297P
Background
Radiotherapy and chemotherapy, or a combination of both have a significant role in the management of cervical cancer. In order to reduce the burden of cervical cancer in a tangible way especially in Indonesia, the need for both modalities demand must be assessed. Considering this, it is necessary to discuss and determine the calculation of the optimal and actual Radiotherapy and Chemotherapy Utilization Rate (RUR and CUR), also the unmet need (gap) between the two rates for cervical cancer in Indonesia.
Methods
Descriptive study of cross-sectional design, total sampling method by taking secondary data from cancer registries and/or internal medical records of participating hospitals with radiotherapy centres in Indonesia in 2019. Data were then separated into hospital data (all cervical cancer cases in the hospital) and RT data (cases from radiotherapy department only).
Results
The total data from the 33 participating hospitals was 4937, divided into 3617 hospital data and 1320 RT data.
The average age of patients was 48-52 years (7-91 years). Patient domicile was mostly from Java Island. Stage III was the most common stage (39.4%). Cervical cancer management was dominated by radiotherapy alone and chemoradiation (28.5% and 27.4%).
Optimal rates can only be based on hospital data that have complete stage attributes.
The optimal, actual RUR and unmet need values were 97.2% (90.9-97.4%), 61.24%, and 36.7% (32.62-37.13%), respectively.
For CUR, the optimal, actual and unmet need values were 87.8% (81-88%), 40%, 54.5% (50.8-55%), respectively.
The actual RUR and CUR for combined data were 70.93% and 39.6%, respectively.
Conclusions
The optimal and actual values of RUR and CUR for cervical cancer in Indonesia still have a large gap, indicating more need for demand of both modalities.
Efforts are needed to increase the actualization of RUR and CUR closer to their optimal rate. Factors affecting RUR and CUR should be explored universally including the patient, clinician, and healthcare system aspects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract